Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 2/7/25 → 2/7/27 |
Funding
- Regeneron Pharmaceuticals: $2.00
24-MEL-14-RG (R3767-ONC-22122): A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
- Arays, Ruta (PI)